Nov 23 (Reuters) - U.S. government will begin distributing
Regeneron Pharmaceuticals Inc's newly authorized
COVID-19 antibody combination therapy starting Tuesday,
beginning with over 30,000 courses, a health official said
during a media call on Monday.
The U.S. Food and Drug Administration on Saturday issued
emergency use authorization for the antibody cocktail to be used
for the treatment of mild to moderate COVID-19 in adults and
children who are at high risk of progressing to severe COVID-19.
(Reporting by Manojna Maddipatla in Bengaluru
Editing by Chizu Nomiyama)